Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey
Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey
复制标题
DOI：
10.1097/gme.0000000000000553
复制
发表时间：
2015-12-01
影响因子：
2.7
通讯作者：
Shifren, Jan L.
中科院分区：
文献类型：
--
作者：
Gass, Margery L. S.;Stuenkel, Cynthia A.;Shifren, Jan L.
目的：进行了一项全国性的调查，以确定使用复合激素治疗（C-HT）的程度，并描述C-HT用户和用户之间的差异激素治疗批准的美国食品和药物管理局（FDA-HT用户）。方法：这项互联网调查招募了3,725名妇女年龄在40至84岁的绝经后或经历更年期过渡。样本加权轻微的年龄，地区，教育和种族，以反映人口属性的基础上US Census data.Results：总体而言，9%的妇女是当前用户的HT，和28%的所有受访者都曾经用户的HT。C-HT使用者占HT曾经使用者的31%，占HT当前使用者的35%，占40至49岁曾经使用者的41%。大约13%的曾经使用者表示目前或过去使用睾酮。使用HT的最常见原因是血管扩张症状（类似于70%）。C-HT使用者更常选择未经批准的HT适应症。在326名C-HT使用者中有4例子宫内膜癌报告，而在738名FDA-HT使用者中没有报告。由于数量较少，尚未确定其意义。结论：这项调查表明全国范围内C-HT的大量使用，以及此类产品的子宫内膜副作用发生率可能更高。需要标准化地收集关于复合激素使用程度及其潜在风险的数据。
Objective: A national survey was conducted to determine the extent of use of compounded hormone therapy (C-HT) and to characterize the differences between C-HT users and users of hormone therapy approved by the US Food and Drug Administration (FDA-HT users).Methods: This Internet survey enrolled 3,725 women aged 40 to 84 years who were postmenopausal or experiencing the menopause transition. The sample was weighted slightly by age, region, education, and race to reflect population attributes based on US Census data.Results: Overall, 9% of women were current users of HT, and 28% of all respondents were ever-users of HT. C-HT users represented 31% of ever-users of HT, 35% of current users of HT, and 41% of ever-users aged 40 to 49 years. Approximately 13% of ever-users indicated current or past use of testosterone. The most cited reason for using HT was vasomotor symptoms (similar to 70%). Nonapproved indications for using HT were selected more often by C-HT users. There were four reports of endometrial cancer among the 326 C-HT users compared with none reported among the 738 FDA-HT users. Significance was not determined because of small numbers.Conclusions: This survey indicates substantial use of C-HT across the country and the possibility of higher rates of endometrial side effects with such products. There is a need for standardized data collection on the extent of use of compounded hormones and their potential risks.